PLURHealthcare · Biotechnology

PLUR Stock Forecast: Pluri, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026

$1.71

−3.39% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 13 of 100 as at 22 Aug 2026 — in the weakest quartile.

Market cap

$18.5M

Ticker Nerd rank

13 / 100

Median analyst target

—

Analysts covering

Total return, dividends reinvested

+6.9%

−12.3%

YTD

−42.8%

−64.5%

From 52W high

−69.9%

From 52W low

+10.3%

$1.55

$5.68

52-week range, adjusted closes · the dot is the last close

Ticker Nerd rank

PLUR stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Pluri, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026

13 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size

Accruals

Growth

Volatility

Revisions

Momentum

Issuance

Value

Quality

Size (89): Smaller than most of the companies we track.

Quality (8): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

PLUR stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on PLUR, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says1 analysts

1 Buy0 Hold0 Sell

Recent analyst actionsNewest first

Date	Firm	Action	Rating	Target
2 June 2025	Alliance Global Partners	Initiates	Buy	$12

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. PLUR appears on the weeks it earns a place.

Estimates

PLUR analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

Pluri, Inc. (PLUR) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation

Trailing P/E: −0.5×
Price / sales: 17.1×
Price / book: −1.4×
EV / EBITDA: −1.9×

Growth & margins

Revenue growth (YoY): −60.9%
Earnings growth (YoY): —
Gross margin: 33.5%
Operating margin: −3913.8%
Net margin: 49.0%

Returns & dividend

Return on equity: 2610.8%
Return on assets: −51.2%
Dividend yield: —

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

PLUR vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology

Company	Market cap	TKN rank
PLURPluri, Inc.	$18.5M	13
CYCNCyclerion Therapeutics, Inc.	$18.2M	26
LEXXLexaria Bioscience Corp.	$18.0M	26
KTTAPasithea Therapeutics Corp.	$18.0M	14
NCELNewCelX Ltd.	$17.4M	17
CALCCalciMedica, Inc.	$19.6M	27
LPCNLipocine, Inc.	$16.8M	36

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Pluri, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest PLUR news & analysis

Plurilock Security Inc. (PLUR:CA) Discusses Corporate Update and Growth Strategy in Defense Contracting Portfolio Transcript

Seeking Alpha · 20 Aug 2026neutral

Plurilock Security Inc. presented a corporate update and discussed its growth strategy within its defense contracting portfolio, as covered in a Seeking Alpha transcript of the discussion.

Why it matters — PLUR watchers would be interested because the company outlined its approach and direction for its defense contracting business, which is a key part of its portfolio.

Pluri's Ever After Foods Expands Cultivated-Protein Platform Through Fishway Acquisition and Strategic Investment

GlobeNewsWire · 17 Aug 2026positive

Pluri's majority-owned food-tech company, Ever After Foods, has expanded its cultivated-protein platform through the acquisition of Fishway and a strategic investment. This adds aquatic cell biology, animal-component-free media capabilities, and a European scientific presence to the company.

Why it matters — For Pluri watchers, this expansion broadens Ever After Foods' cultivated-protein capabilities and geographic scientific reach under the company's majority ownership.

Pluri Advances Commercial Expansion Through Its Subsidiary Cellav, Completing Regulatory Registration in the UK

GlobeNewsWire · 28 July 2026positive

Pluri's consumer-health subsidiary, Cellav, completed regulatory registration in the UK for its regenerative aesthetics product Regenativo+, paving the way for a commercial launch in a market estimated at roughly $900 million annually.

Why it matters — This milestone advances Pluri's commercialization strategy by opening a significant new market and laying the groundwork for broader international expansion of its regenerative aesthetics portfolio.

FAQ

Frequently asked questions about PLUR stock

Is PLUR stock a buy right now?

Of the 1 analysts covering Pluri, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Pluri, Inc. 13 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank PLUR?

As at 22 Aug 2026, Pluri, Inc. ranks 13 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (89 of 100).

What is the PLUR stock forecast for 2030?

No analyst covering Pluri, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PLUR are extrapolating price history, which says nothing about the business.

How has PLUR stock performed over the past year?

Pluri, Inc. returned -64.5% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Pluri, Inc. do?

Pluri Inc. is a biotechnology company focusing on cell-based therapeutics and technology-driven innovations to address complex medical conditions.

What is the latest news on PLUR?

The most recent item we track (Seeking Alpha, 20 Aug 2026): "Plurilock Security Inc. (PLUR:CA) Discusses Corporate Update and Growth Strategy in Defense Contracting Portfolio Transcript". Plurilock Security Inc. presented a corporate update and discussed its growth strategy within its defense contracting portfolio, as covered in a Seeking Alpha transcript of the discussion.

Company

About Pluri, Inc.

Pluri Inc. is a biotechnology company focusing on cell-based therapeutics and technology-driven innovations to address complex medical conditions. The primary function of Pluri is to harness advanced cell-production technologies to develop a wide array of potential therapies that may transform treatment modalities across various sectors. Pluri's expertise lies in using proprietary 3D cell culture platforms to cultivate placental cells, which are then utilized in regenerative medicine applications. These applications have significant implications for industries including orthopedics, cardiovascular health, and autoimmune diseases. The company's innovative approach seeks to provide scalable and sustainable solutions in tissue engineering and organ regeneration, aiming to meet unmet medical needs globally. Pluri Inc.'s commitment to research and development in biotechnology underlines its pivotal role in pioneering new therapeutic strategies, making it a significant entity within the healthcare and life sciences sectors. Established to impact global health, Pluri continues to explore a dynamic intersection between cutting-edge technology and medical sciences, contributing to a potential shift in how chronic illnesses and acute health challenges are managed.

CEO Mr. Yaacov Yanay · 127 employees · Israel · https://www.pluri-biotech.com